Dear Editor
The control of CD95 expression is a key factor for the regulation of apoptosis in several cellular systems. Although different transcription factors, such as p53, SP-1, NF-κB, GA-binding protein and AP-1 have been implicated in the regulation of CD95 promoter in various cellular contexts,1,2,3 the molecular events regulating constitutive and inducible CD95 gene expression have not been fully elucidated. Interferon-γ (IFN-γ) increases CD95 expression and CD95-induced apoptosis in several cell types.4 We hypothesized that such upregulation of CD95 expression and signaling could be mediated by the interferon regulatory factor-1 (IRF-1), a tumor-suppressor transcription factor involved in the immune-regulatory activity of interferons. IRF-1 is induced in response to IFN-γ and to a variety of other cytokines, and has been shown to be involved in tumor suppression, growth regulation, cell differentiation and apoptosis.5,6,7,8 Several studies have contributed to define IRF-1 as a regulator of apoptosis: IRF-1 mRNA is induced by IFN-γ earlier and more strongly than other apoptosis-related genes, suggesting a direct involvement of IRF-1 in the transactivation of proapoptotic gene families. Moreover, IRF-1 has been demonstrated to mediate DNA damage-induced apoptosis in mitogen-activated T lymphocytes, a process that does not require p53.9 Nevertheless, the specific role of IRF-1-inducible genes in IRF-1-dependent apoptotic pathway remains unknown. By using a dedicated computer program, we found two consensus binding sequences for IRF-1 in the human CD95 promoter sequence. In order to verify whether IRF-1 was able to bind the CD95 promoter, we synthesized two double-stranded oligonucleotides whose sequences reproduce the CD95 promoter region encompassing the two putative IRF-1-binding sites. Both probes were 32P labeled and utilized in electrophoretic mobility shift assay (EMSA) experiments with nuclear extracts obtained from U937 monocytic cells stimulated with IFN-γ for 2 h. In Figure 1a, we show the appearance of two inducible IRF-1-binding complexes, whose specificity was demonstrated by competition assays with a molar excess of unlabeled wild-type probe or of an unrelated oligomer. Moreover, an anti-IRF-1 polyclonal antibody was able to induce a supershift that could be abrogated by a specific neutralizing peptide. To assess whether IRF-1 binding plays a functional role in trans-activation of the human CD95 promoter, we performed the luciferase reporter gene assay in a recipient cell system using wild-type and mutated sequences derived from the CD95 promoter. As described in Figure 1b, the CD95 promoter region from nt −1435 to nt +236 and a series of mutants were cloned upstream the luciferase gene in the PGL2 basic vector and the resulting constructs (PGL-CD95, mutant-1, -2 and -3) were transiently cotransfected in TK- ts13 cells together with an IRF-1 expression vector (pAct) or an empty control vector (pActC). The luciferase expression driven by the entire CD95 promoter (PGL-CD95) was enhanced approximately 55 folds in the presence of the IRF-1 expression vector. The mutated CD95 promoter constructs M1 and M2, containing IRF-1-binding site 1 and IRF-1-binding site 2, respectively, were both specifically trans-activated by IRF-1, although to a lesser extent (about 14 folds). As expected, the M3 construct, a deletion mutant without any IRF-1-binding site, was not substantially activated by IRF-1. In order to understand the role of IRF-1 in CD95 gene regulation, we analyzed the kinetics of IRF-1 and CD95 mRNA induction by IFN-γ in peripheral blood-derived human monocytes and in U937 monocytic cells. After total RNA isolation, quantitative real-time RT-PCR was performed to evaluate IRF-1 and CD95 mRNA levels in cells stimulated up to 24 h with IFN-γ. Target genes (IRF-1 and CD95) were coamplified with the endogenous 18 S gene, and their levels were normalized on the basis of the endogenous control. As shown in Figure 1c, we observed a tight correlation between IRF-1 and CD95 gene expression levels both in monocytes and in U937 cells. This observation suggests the possibility that CD95 levels may be influenced by the amount of IRF-1 present in the cell. In order to investigate the effect of IRF-1 inhibition on CD95 expression, we performed a relative quantification of IRF-1 and CD95 transcript levels in monocytes or U937 cells treated with IRF-1 antisense oligodeoxynucleotides (ODN). In Figure 1d, we show that treatment of monocytes with antisense ODN for 24 h results in about 75% inhibition of IFN-γ-induced IRF-1 upregulation, with a consequent significant reduction of CD95 levels. Similar results were obtained in U937 cells. Moreover, the effect of IRF-1 inhibition on CD95 protein expression paralleled the effect on gene expression, as shown by cytofluorimetric analysis in Figure 1e. To investigate the possible role of IRF-1 in CD95-mediated apoptosis, we targeted IRF-1 expression with antisense ODN and evaluated the levels of cell death induced by an agonistic anti-CD95 antibody in U937 cells. Cells were stimulated with IFN-γ in the presence or absence of IRF-1 antisense or missense ODN and treated 4 h with anti-CD95 antibody. The percentage of apoptotic cells was determined by the Annexin V–propidium iodide standard assay. According to previous reports, we found that IFN-γ stimulation increased CD95-mediated apoptosis of U937 cells. On the other hand, treatment with IRF-1 antisense ODN significantly inhibited CD95-induced cell death, whereas treatment with missense ODN did not reproduce the same effect (Figure 1f). These observations suggest that IRF-1 contributes to IFN-γ-mediated sensitization of monocytic cells to CD95-induced apoptosis.
CD95 induction by IRF-1, while not being the only event responsible for the proapoptotic activity of IRF-1, may contribute to explain the role of this transcription factor in determining susceptibility to cell death. Since IRF-1 has been demonstrated to mediate caspase-1 gene induction, the proapoptotic activity of IRF-1 has been in some cases ascribed to increased caspase-1 expression and activation.10 However, whereas the importance of caspase-1 in the production of inflammatory cytokines is widely recognized, its role in apoptosis remains controversial and seems in most cases subordinated to caspase-3 and -8 activation. It has been recently reported that the release of IFN-γ by cytotoxic T cells upregulates CD95 expression on the surface of target cells and facilitates perforin-independent target cell lysis.11 IFN-γ-mediated CD95 upregulation may play a role in the feedback regulation of an immune response by clearing APC that are no more necessary for antigen presentation. In this view, IFN-γ released by CTL may activate IRF-1, which would contribute to CD95 upregulation and sensitization of monocytes to CD95-induced apoptosis. Since macrophages derived from IRF-1−/− mice are refractory to cytotoxicity induced by stimulation with LPS plus IFN-γ,12 it would be interesting to investigate the possible involvement of CD95 in this process. Our observation that IRF-1 is able to modulate CD95 levels may have potential implications also in nonhematopoietic cells, particularly where IRF-1 nullizygosity has been shown to determine an increased resistance to pathological cell death. IRF-1 expression is increased after cerebral ischemia in damaged regions of the brain, and IRF-1 knockout mice show a substantial reduction of infarctuated area and neurological deficits. Since CD95 has been reported to mediate ischemia/reperfusion-induced apoptosis, which involves death receptor-mediated damage, it would be interesting to evaluate the possible contribution of IRF-1 to the induction of CD95 expression in ischemic neurons. In conclusion, we provide evidence that IRF-1 plays a role in IFN-γ-induced CD95 expression and sensitivity of monocytic cells to CD95-mediated apoptosis. This study may contribute to clarify both the mechanisms that control CD95 expression and the links between IRF-1 and the transcriptional regulation of apoptosis.
References
Chan H et al. (1999) Mol. Cell. Biol. 19: 2098–2108
Owen-Schaub et al. (1995) Mol. Cell. Biol. 15: 3032–3040
Li XR et al. (1999) J. Biol. Chem. 274: 35203–35210
Ossina NK et al. (1997) J. Biol. Chem. 272: 16351–16357
Willman CL et al. (1993) Science 259: 968–971.
Harada H et al. (1993) Science 259: 971–974.
Tanaka N, Kawakami T, Taniguchi T (1993). Mol. Cell. Biol. 13: 4531–4538.
Liebermann DA, Hoffman B (1994) Stem Cells. 12: 352–369.
Tamura T et al. (1995) Nature 376: 596–599.
Kim EJ et al. (2002) J. Cell. Biochem. 85: 369–380
Mullbacher A et al. (2002) J. Immunol. 169: 145–150
Iadecola C et al. (1999) J. Exp. Med. 189: 719–727
Acknowledgements
We are grateful to Dr. Y Nakanishi and Dr. T Taniguchi for kindly providing CD95 promoter and IRF-1 expression vector, respectively. We thank Dr. Nicola Marziliano for helping in quantitative PCR measurements. A Zeuner and CG Messina are recipient of FIRC fellowships. This work was supported by AIRC grants.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Conte, E., Manzella, L., Zeuner, A. et al. Involvement of interferon regulatory factor-1 in monocyte CD95 expression and CD95-mediated apoptosis. Cell Death Differ 10, 615–617 (2003). https://doi.org/10.1038/sj.cdd.4401213
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4401213
This article is cited by
-
XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis
Cell Death & Disease (2018)
-
Inhibition of cellular FLICE-like inhibitory protein abolishes insensitivity to interferon-α and death receptor stimulation in resistant variants of the human U937 cell line
Apoptosis (2011)